Mustang Bio Inc.'s gene therapy MB-102 was found to be safe and well tolerated in a phase 1 study to test treatment of two types of blood cancer.
The chimeric antigen receptor T-cell, or CAR-T, drug was used to treat blastic plasmacytoid dendritic cell neoplasm, or BPCDN, and acute myeloid leukemia, or AML, in two separate arms. One patient being treated for BPCDN achieved a complete response, meaning the cancer was no longer present, for at least six months. This was the first-ever reported complete response for the rare blood disease, the company said in the news release.
Patients in both groups received one dose of MB-102, with seven of the 14 patients enrolled treated to date, according to the findings presented at the American Society of Hematology meeting in Atlanta.
BPCDN is a rare and incurable blood cancer with a median survival of less than 18 months. AML is a cancer characterized by rapid growth of abnormal white blood cells.
Mustang Bio is a subsidiary of Fortress Biotech Inc.
